Multiple sclerosis: Relating MxA transcription to anti-interferon-β- neutralizing antibodies

Neurology

Volumn 68, Issue 12, 2007, Pages 958-959

  Hoffmann, L A ^a   Krumbholz, M ^a   Faber, H ^a   Kuempfel, T ^a   Starck, M ^b   Pollmann W ^b   Meinl, E ^a   Hohlfeld, R ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b Marianne Strauss Hospital   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BETA1A INTERFERON; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; INTERFERON ANTIBODY; INTERFERON BETA SERINE; MYXOVIRUS RESISTANCE PROTEIN A; NEUTRALIZING ANTIBODY; TRANSCRIPTION FACTOR PAX2;

ANTIBODY DETECTION; ANTIVIRAL ACTIVITY; ARTICLE; BIOLOGICAL MONITORING; BLOOD SAMPLING; CELL PROTECTION; CONTROLLED STUDY; CYTOPATHOGENIC EFFECT; CYTOTOXICITY; DRUG SENSITIVITY; ENCEPHALOMYOCARDITIS VIRUS; EXON; EXPANDED DISABILITY STATUS SCALE; FEMALE; GENE EXPRESSION; GENETIC TRANSCRIPTION; HOUSEKEEPING GENE; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LABORATORY; MAJOR CLINICAL STUDY; MALE; MONITOR; MULTIPLE SCLEROSIS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RECURRENT DISEASE; TREATMENT DURATION;

ADULT; ANTIBODIES; BIOLOGICAL MARKERS; FEMALE; GTP-BINDING PROTEINS; HUMANS; INTERFERON-BETA; MALE; MULTIPLE SCLEROSIS; PREDICTIVE VALUE OF TESTS; TIME FACTORS; TRANS-ACTIVATION (GENETICS); UP-REGULATION;

EID: 34147157175     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000257128.53775.62     Document Type: Article

References (7)

1. Pachner AR. Measurement of antibodies to interferon beta in patients with multiple sclerosis. Arch Neurol 2001;58:1299-1300.
2. Vartanian TK, Zamvil SS, Fox E, Sorensen PS. Neutralizing antibodies to disease-modifying agents in the treatment of multiple sclerosis. Neurology 2004;63(11 suppl 5):S42-S49.
3. Sorensen PS, Ross C, Clemmesen KM, et al. Clinical importance of neutralising antibodies against interferon beta in patients with relapsing-remitting multiple sclerosis. Lancet 2003;362:1184-1191.
4. Pachner AR, Bertolotto A, Deisenhammer F. Measurement of MxA mRNA or protein as a biomarker of IFNbeta bioactivity: detection of antibody-mediated decreased bioactivity (ADB). Neurology 2003;61(9 suppl 5):S24-S26.
5. Pachner AR, Dail D, Pak E, Narayan K. The importance of measuring IFNbeta bioactivity: monitoring in MS patients and the effect of anti-IFNbeta antibodies. J Neuroimmunol 2005;166:180-188.
6. Pachner AR, Narayan K, Pak E. Multiplex analysis of expression of three IFNbeta-induced genes in antibody-positive MS patients. Neurology 2006;66:444-446.
7. Petersen B, Bendtzen K, Koch-Henriksen N, Ravnborg M, Ross C, Sorensen PS. Danish Multiple Sclerosis Group. Persistence of neutralizing antibodies after discontinuation of IFNbeta therapy in patients with relapsing-remitting multiple sclerosis. Mult Scler 2006;12:247-252.